IPF-023

Idiopathic Pulmonary Fibrosis (IPF)

Sydney 70 years old male Australia Total Cost: 236

Patient Condition

The patient visited the hospital for progressive shortness of breath and dry cough for 18 months and had a history of smoking (25 pack-years). HRCT showed honeycomb lungs and grid shadows at the base of both lungs. Lung function: FVC 56% predicted, DLCO 40% predicted. 6MWD 310m, mMRC score 3. Diagnosis of IPF.

Treatment Timeline

PhaseDetailsDate
diagnostic assessment
treatment initiation
Treatment monitoring (months 1-12)
Maintenance treatment (Months 13-24)

Treatment Outcome

beforeFVC accounted for 56% of predicted value, DLCO accounted for 40% of predicted value, 6MWD 310m, mMRC score 3
afterAfter 24 months of treatment, FVC accounted for 51% of the predicted value (annual decline rate of approximately 2.5%), DLCO accounted for 35% of the predicted value, 6MWD was 335m, and mMRC score dropped to level 2
highlightAfter 24 months of nittedanib combined with pulmonary rehabilitation, FVC decline was delayed, exercise tolerance was improved, and mMRC score was improved.